ESMO 2025: Superior Outcomes With Reduced NIVO+IPI Dose in Advanced Melanoma

At ESMO 2025, Hildur Helgadottir, MD, PhD, Associate Professor at Karolinska Comprehensive Cancer Center, presented a Swedish real-world study comparing traditional doses of ipilimumab plus nivolumab with a lower dose in patients with metastatic melanoma. The study showed that the lower NIVO+IPI regimen had superior efficacy, possibly related to its improved tolerability and the higher number of doses received. The results support broader use of this treatment regimen, despite its current lack of regulatory approval.